Related Experiment Video
Updated: Mar 2, 2026

In Situ Immunofluorescent Staining of Autophagy in Muscle Stem Cells
Published on: June 12, 2017
Stachydrine Protects Against Pressure Overload-Induced Cardiac Hypertrophy by Suppressing Autophagy
Tong-Tong Cao1, Hui-Hua Chen1, Zhiwei Dong2
1Department of Pathology, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Insights
Stachydrine, a natural compound, inhibits excessive autophagy and reactive oxygen species (ROS) production by blocking NADPH oxidase 2 (NOX2) activation. This mechanism effectively reduces cardiac hypertrophy in pressure overload heart failure models.
Area of Science:
- Cardiovascular Research
- Cellular Biology
- Pharmacology
Background:
- Autophagy is crucial for cardiomyocyte health but becomes maladaptive in heart failure.
- Excessive autophagy contributes to pressure overload-induced cardiac hypertrophy.
- Understanding Stachydrine's inhibitory mechanisms is key to treating heart failure.
Purpose of the Study:
- To investigate how Stachydrine inhibits pressure overload-induced cardiac hypertrophy.
- To determine Stachydrine's effects on NADPH oxidase activation, ROS production, and autophagy.
- To elucidate the molecular pathways involved in Stachydrine's cardioprotective effects.
Main Methods:
- Administered Stachydrine to Wistar rats post-Transverse Aortic Constriction (TAC) and to Angiotensin II-stimulated H9c2 cells.
- Assessed NADPH oxidase 2 (NOX2) activation by measuring p47phox and p67phox translocation via Western blot and immunofluorescence.
- Quantified intracellular ROS using DCF-DA fluorescence and autophagic flux with mRFP-GFP-LC3 live-cell imaging.
Main Results:
- Stachydrine inhibited Angiotensin II-induced excessive autophagy in H9c2 cells.
- Stachydrine blocked p47phox hyperphosphorylation, reduced p47phox/p67phox membrane translocation, and inhibited NOX2 activity.
- Reduced ROS generation and ameliorated TAC-induced cardiac hypertrophy, dysfunction, and excessive autophagy in vivo.
Conclusions:
- Regulating NOX2 is critical when autophagy is highly activated.
- Stachydrine's inhibition of NOX2 reduces ROS production, thereby inhibiting cardiac hypertrophy.
- These findings suggest Stachydrine has significant potential for clinical application in heart failure treatment.
Background:
Autophagy is required for the maintenance of cardiomyocyte homeostasis. However, excessive autophagy plays a maladaptive role in pressure overload-induced heart failure. To identify mechanisms by which Stachydrine inhibits pressure overload-induced cardiac hypertrophy, we determined inhibitory activities against activation of NADPH oxidase, reactive oxygen species(ROS) production and excessive activation of autophagy.
Methods:
Stachydrine was administered intragastrically to Wistar rats after Transverse aortic constriction(TAC) and H9c2 cells were treated with Stachydrine after Angiotension II stimulation. The activation of NADPH oxidase2 required the membrane translocation of p47phox and p67phox. Cell membrane fraction was isolated by ultracentrifuge in sucrose. The expression of p67phox, p47phox, gp91phox subunit in the cell membrane were determined by western blot. The combination of p67phox and gp91 phox subunit was detected by immunofluorescence staining. The expression of phosphorylated p47phox subunit was determined by western blot. The intracellular ROS were measured with DCF-DA fluoresence. The autophagic flux was measured by recording the fluorescence emission of the fusion protein mRFP-GFP-LC3 by dynamic live-cell imaging. Reuslts: We report here that stachydrine, a major constituent of Leonurus heterophyllus Sweet, inhibited AngII-induced excessive autophagy within H9c2 cells. Stachydrine blocked the over phosphorylation of the p47phox subunit, decreased the translocation of p47phox and p67phox to the membrane, inhibited the activity of NOX2, and reduced the generation of ROS. We also demonstrated that stachydrine ameliorated TAC-induced cardiac hypertrophy, dysfunction and excessive autophagy in vivo.
Conclusions:
Our study highlights the importance of regulating NOX2 when autophagy is obviously activated. By inhibiting NOX2, Stachydrine inhibits ROS production, thus exerting a remarkable activity of inhibiting hypertrophy, which could have considerable effect on clinical practice.
Related Concept Videos
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Antihypertensive Drugs: Action of β1 Blockers
Heart Failure Drugs: Diuretics

